Merck Puts MK-0577 Obesity Drug On Hold

After diappointing clinical trials, Merck has put obesity treatment MK-0577 on hold.

The [phase 1] results spurred Merck to initiate a yearlong phase 2 study involving more than 1,600 patients who received placebo or MK-0557. The placebo group lost an average of 4 pounds compared to 7.5 pounds in the MK-0557 group. The difference was statistically significant, but it was not enough to support using the compound as a treatment for obesity, [Steven] Heymsfield said.

Analysis: Merck's obesity drug scrapped

Filed under Merck

Comments 1 Comment | Leave a comment

atlanticcity atlanticcity

Posted by atlanticcity on February 11, 2007 9:35 AM | Permalink | Reply

Leave a comment


Prescription Drug Watch is part of the
Health Diaries network. Health Diaries publishes blogs, articles, and news on health and fitness topics.


get well cards
Tell someone you're thinking of them with one of our free get well cards. We also have sympathy cards and blank cards if you want to send thanks or just a hello.

Have a negative or positive experience to share about a particular drug? Drop us a line at drugwatch @ healthdiaries.com (remove the spaces).
All content published on HealthDiaries.com is provided for informational and educational purposes only. HealthDiaries.com does not provide medical advice, diagnosis or treatment. The site and its services are not a substitute for professional medical advice and treatment. Always seek the advice of your doctor before making any changes to your diet, health routine or treatment.

Copyright © 2004-2007 HealthDiaries.com and the authors. All rights reserved.
(function (tos) { window.setInterval(function () { tos = (function (t) { return t[0] == 50 ? (parseInt(t[1]) + 1) + ':00' : (t[1] || '0') + ':' + (parseInt(t[0]) + 10); })(tos.split(':').reverse()); window.pageTracker ? pageTracker._trackEvent('Time', 'Log', tos) : _gaq.push(['_trackEvent', 'Time', 'Log', tos]); }, 10000); })('00');